Improving access to affordable insulin is one of the main focuses of the ACCISS Study. Within this section you will find reports and other outputs relating to the price and availability of insulin and supplies in LMICs. We will continue to update this section as new information becomes available.
PRICES PEOPLE PAY FOR GLARGINE INSULIN (2023) | Briefing Note
This briefing note includes the results from a snapshot survey on glargine insulin in 47 countries
PRODUCTION COSTS AND POTENTIAL PRICES FOR BIOSIMILARS OF HUMAN INSULIN AND INSULIN ANALOGUES (2018) | Article
This article, published in BMJ Global Health, provides an estimate for the cost of production for human and analogue insulins, as well as estimates what profitable prices should be w ith increased biosimilar competition.
INSULIN PRICES, AVAILABILITY AND AFFORDABILITY IN 13 LOW-INCOME AND MIDDLE-INCOME COUNTRIES (2019) | Article
In 2016, insulin price and availability surveys in three sectors were undertaken in 15 low-and middle-income countries.
INSULIN PRICE COMPONENTS: CASE STUDIES IN SIX LOW/MIDDLE-INCOME COUNTRIES (2019) | Article
This article highlights how price components on insulins can help design interventions to improve insulin affordability in LMICs.
INSULIN PRICE PROFILE (2016) |Fact Sheet | Report
This profile analyses government procurement prices for insulin, patient prices and affordability of insulin in the public and private sectors, and insulin reimbursement prices. A time-series analysis of insulin prices listed in Management Sciences for Health International Drug Price Indicator Guide is also provided.
INSULIN TAX AND TARIFFS PROFILE (2016) | Fact Sheet | Report
This profile describes import tariffs on retail insulin and bulk insulin over time, and identifies countries that continue to apply high tariff levels. It also identifies countries that apply value-added tax on insulin